Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InBody CoXKRX:041830 -3.60%86 Operating Margin % is 24.22% as of Jun. 2026, which is 2% above its 10-year median of 23.68. GuruFocus rates XKRX:041830 with a GF Score™ of 86/100 and a GF Value™ of ₩35,473.99 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, InBody Co ranks better than 84.79% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. InBody Co's Operating Income for the
three
months ended in Jun. 2026 was ₩17,743 Mil. InBody Co's Revenue for the
three
months ended in Jun. 2026 was ₩73,254 Mil. Therefore, InBody Co's Operating Margin % for the quarter that ended in Jun. 2026 was 24.22%.
Warning Sign:
InBody Co Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -5.2%.
The historical rank and industry rank for InBody Co's Operating Margin % or its related term are showing as below:
XKRX:041830'
s Operating Margin % Range Over the Past 10 Years
Min: 15.71 Med: 23.68 Max: 27.6
Current: 18.98
XKRX:041830's Operating Margin % is ranked better than 84.79% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 3.37
vs XKRX:041830: 18.98
InBody Co's 5-Year Average Operating Margin % Growth Rate was -5.20% per year.
InBody Co's Operating Income for the
three
months ended in Jun. 2026 was ₩17,743 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was ₩50,098 Mil.
InBody Co (XKRX:041830) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
InBody Co Operating Margin % Related Terms
InBody Co Operating Margin % Historical Data
* Premium members only.
The historical data trend for InBody Co's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:041830 vs ABT, SYK, MDT: Operating Margin % Comparison
For the Medical Devices subindustry, InBody Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InBody Co Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InBody Co's Operating Margin % distribution charts can be found below:
* The bar in red indicates where InBody Co's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
InBody Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InBody Co (XKRX:041830) has a Operating Margin % of 24.22% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on InBody Co and its competitors. This is near median its historical median of 23.68. Over the past decade, InBody Co's Operating Margin % has ranged from 15.71 to 27.60. According to the industry distribution chart, InBody Co ranks #124 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 15.2%.
Is InBody Co's Operating Margin % too high?
InBody Co's current Operating Margin % of 24.22% is near median its 10-year median of 23.68. Over the past 10 years, this metric has ranged from a low of 15.71 to a high of 27.60. The Medical Devices & Instruments industry median Operating Margin % is 3.37. InBody Co's value of 24.22% is 618.7% above this industry median. Based on the distribution chart, InBody Co ranks #124 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, InBody Co has a GF Score™ of 86/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InBody Co's Operating Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, InBody Co ranks #124 out of 815 companies for Operating Margin %. This places InBody Co in the top 15% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 3.37. InBody Co's value of 24.22% is 618.7% above this benchmark. Historically, InBody Co's own Operating Margin % has ranged from 15.71 to 27.60 over the past decade. While the company's 10-year median is 23.68 vs. the industry median of 3.37, InBody Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.37, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InBody Co's current Operating Margin % of 24.22% is 618.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on InBody Co and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InBody Co's current Operating Margin % is 24.22%, which is near median its own 10-year median of 23.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InBody Co stock overvalued right now?
Based on GuruFocus' analysis, InBody Co (XKRX:041830) is currently considered Significantly Overvalued. The stock's GF Value™ is ₩35,473.99, compared to a current price of ₩58,900.00 — trading 66% above its estimated fair value. The current Operating Margin % is 24.22%, which is near median its 10-year median of 23.68 and 618.7% above the Medical Devices & Instruments industry median of 3.37. InBody Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For InBody Co (XKRX:041830), the current Operating Margin % is 24.22% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InBody Co (XKRX:041830) Overvalued in 2026?
Based on GuruFocus' analysis, InBody Co stock appears to be overvalued.
The current stock price of ₩58,900.00 is trading 66% above its estimated GF Value™ of ₩35,473.99.
GuruFocus considers InBody Co to be Significantly Overvalued.
Key valuation signals for XKRX:041830:
Operating Margin %: 24.22% (near median its 10-year median of 23.68)
GF Value™: ₩35,473.99 vs. price of ₩58,900.00 (66% above fair value)
Industry Position: 618.7% above the Medical Devices & Instruments median (#124 of 815)
No single metric tells the full story. See the XKRX:041830 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InBody Co Ltd is a Korea-based company engaged in the manufacturing and distribution of body composition analyzers. The company mainly produces body composition analyzers under the brand name InBody and Lookin'Body. It's InBody series products include InBody720, InBody570, InBody230, InBody J30, and InBody S10.
86GF Score
Get the complete analysis for XKRX:041830
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:041830 has been successfully added to your 
